Background {#Sec1}
==========

Patients with end-stage renal disease (ESRD) experience a high burden of early death and cardiovascular disease (CVD), particularly within the first year after dialysis initiation (189 to 382 per 1000 person-years) \[[@CR1]--[@CR7]\]. Furthermore, CVD contributes to \> 50% of all ESRD deaths with known causes \[[@CR8]\].

Recent literature suggests that acute kidney injury may also be associated with increased risk of CVD events \[[@CR9]--[@CR16]\]. Acute kidney injury is associated with increased inflammatory cytokines \[[@CR17]\], which may increase risk of subsequent CVD events \[[@CR18]\] via endothelial dysfunction or plaque rupture \[[@CR19]\]. Of note, abrupt decline in kidney function during the three months before initiating hemodialysis is a strong, independent risk factor for early death after ESRD onset \[[@CR20]\]. Dialysis-requiring acute kidney injury (AKI-D) is not an uncommon precipitant to ESRD \[[@CR21], [@CR22]\] and may be an important contributor to the high early mortality rates and excess CVD risk in incident ESRD patients. However, few studies have examined outcomes in this ESRD subgroup.

In a diverse, community-based cohort, we examined the association between AKI-D and short-term death and CVD outcomes. We hypothesized that patients with incident ESRD due to AKI-D are at higher short-term risk for death and CVD events compared to patients with incident ESRD that is not attributable to AKI-D, even after controlling for known vascular risk factors. Furthermore, we hypothesized that patients who recover adequate kidney function after AKI-D to discontinue dialysis would experience better outcomes. Our goal was to provide insight into the clinical implications of AKI-D as well as recovery from AKI-D to improve risk stratification and guide development of more tailored preventative strategies.

Methods {#Sec2}
=======

Source population {#Sec3}
-----------------

Kaiser Permanente Northern California (KPNC) is a large, integrated health care delivery system that currently provides comprehensive inpatient and outpatient care for \> 4.1 million members in the greater San Francisco Bay Area. Its membership is highly diverse and representative of the local surrounding and statewide population \[[@CR23]\], with nearly all aspects of care captured through KPNC's electronic medical record system.

This study was approved by the institutional review boards at KPNC and University of California, San Francisco (\#16--20030). We obtained a waiver of informed consent given the nature of the study.

Study sample {#Sec4}
------------

We identified all adult (age ≥18 years) KPNC members who developed AKI-D or who initiated chronic hemodialysis between January 2009 and September 2015 and who had ≥12 consecutive months of health plan membership and pharmacy benefits before initiation of renal replacement therapy (RRT) in order to ensure adequate capture of relevant comorbidities and prescription medication use. We defined AKI-D as receipt of RRT during hospitalization in the absence of any pre-admission RRT (dialysis or transplant). Inpatient RRT included receipt of peritoneal dialysis, hemodialysis, and hemofiltration that were identified using *International Classification of Diseases, Ninth Revision* (ICD-9) procedure codes (54.98, 39.95) and *Current Procedural Terminology* codes (90,935, 90,937, 90,945, 90,947, 90,999). We previously demonstrated the accuracy of these codes to identify AKI-D across the spectrum of pre-admission estimated glomerular filtration rate (eGFR) based on adjudication of medical records by a board-certified nephrologist in a random sample of 100 patients (positive predictive value 94%) \[[@CR24]\]. We excluded one patient with pre-hospitalization eGFR \> 150 mL/min/1.73m^2^ because of concerns about the accuracy of the value. Patients initiating chronic hemodialysis without preceding AKI-D were ascertained through a comprehensive health system ESRD Treatment Registry \[[@CR21], [@CR22], [@CR25]\]. For incident ESRD patients who did not have AKI-D, we studied only hemodialysis patients because risk factors for early death and CVD events may differ according to ESRD treatment modality, and because hemodialysis is the most common initial modality in the U.S. \[[@CR8]\].

Predictor variable {#Sec5}
------------------

The two primary comparisons were 1) between patients with incident ESRD due to non-recovery from AKI-D versus incident ESRD patients who did not have AKI-D and 2) between AKI-D patients who did versus who did not recover adequate kidney function to discontinue dialysis. Recovery from AKI-D was defined as being alive and no longer needing RRT for ≥4 weeks at 90 days after initiation of acute RRT. We required that patients remain alive for ≥4 weeks to reduce potential misclassification due to withdrawal of care. To be comprehensive, recovery could occur during the index hospitalization or in the outpatient setting after hospital discharge. We used recovery status at 90 days, as patients are conventionally considered to have ESRD using this cutoff \[[@CR26]\].

Follow-up and outcome variables {#Sec6}
-------------------------------

We focused on short-term clinical outcomes of AKI-D because we *a priori* hypothesized that the effect of AKI-D would gradually fade over time, consistent with findings regarding the potential effect of acute kidney injury on other outcomes \[[@CR16]\]. Starting 90 days after RRT initiation, patients were censored at health plan disenrollment or death up to 365 days. We excluded patients censored before 90 days post-RRT initiation because 90-day survival was necessary to ascertain recovery from AKI-D, as well as patients with hospitalizations ≥90 days after acute RRT initiation.

Primary clinical outcomes included all-cause death, heart failure, acute coronary syndrome (ACS), and acute ischemic stroke or transient ischemic attack (TIA) occurring between 90 days and 455 days (i.e., up to one year later) after RRT initiation using validated diagnosis codes and algorithms with high positive predictive values based on data found in comprehensive health plan electronic medical records (codes available upon request) \[[@CR27], [@CR28]\]. Vital status was based on comprehensive information from health plan administrative and hospital discharge databases, member proxy reporting, Social Security Administration vital status files, and California state death certificate information \[[@CR27], [@CR29]\].

Covariates {#Sec7}
----------

We relied primarily on electronic health record data that were standardized and linked at the patient-level in the Kaiser Permanente Virtual Data Warehouse \[[@CR21], [@CR28], [@CR30]--[@CR32]\]. Demographic and lifestyle characteristics included age, gender, self-reported race/ethnicity, and tobacco use. Relevant pre-admission comorbidities (heart failure, coronary disease, ischemic stroke, peripheral artery disease, atrial fibrillation, mitral/aortic valvular disease, hypertension, diabetes mellitus, dyslipidemia, prior hospitalized bleed, thyroid disease, cirrhosis, lung disease, dementia, and depression) were defined using validated diagnostic or procedure codes \[[@CR33]\]. We ascertained outpatient body mass index and systolic blood pressure, as well as relevant outpatient laboratory test results (eGFR using the CKD-EPI equation, urine dipstick proteinuria, high-density lipoprotein, low-density lipoprotein, and hemoglobin levels) and receipt of medications (angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, calcium channel blockers, diuretics, aldosterone receptor antagonists, alpha blockers, antiarrhythmic agents, nitrates, other vasodilators, non-aspirin antiplatelet agents, low-molecular-weight heparin, statins, other lipid-lowering agents, anti-diabetic agents, and non-steroidal anti-inflammatory drugs).

Statistical approach {#Sec8}
--------------------

All analyses were conducted using SAS, version 9.3 (Cary, N.C.). Baseline characteristics were compared across exposure categories using ANOVA for continuous variables and χ^2^ tests for categorical variables.

We calculated crude incidence rates and 95% confidence intervals for outcomes by exposure group. After confirming no violation of the proportional hazards assumption using visual examination of Kaplan-Meier curves and ln(−ln) plots and assessment of Schoenfeld residuals, we conducted Cox regression models for each outcome of interest with adjustment for demographics, tobacco use, comorbidities, vital signs, and medication use.

We also conducted sensitivity analyses using AKI-D patients with a pre-existing eGFR \> 24 ml/min/1.73 m^2^, which was the 75th percentile threshold for this subset of our cohort (ESRD due to AKI-D *n* = 434, ESRD not due to AKI-D *n* = 3772, recovered AKI-D *n* = 942).

Results {#Sec9}
=======

Baseline characteristics {#Sec10}
------------------------

We initially identified 13,213 hospitalized patients who received inpatient RRT and 6414 patients who initiated chronic hemodialysis as outpatients between January 2009 and September 2015. After applying exclusion criteria, our final sample included 1865 patients with incident ESRD due to AKI-D (i.e., non-recovery from AKI-D), 3772 patients with incident ESRD not due to AKI-D, and 1347 AKI-D patients who recovered within 90 days after RRT initiation.

Compared to incident ESRD patients without AKI-D, patients with incident ESRD due to AKI-D were older, more likely to be white, and generally had a higher burden of baseline CVD (Table [1](#Tab1){ref-type="table"}). Compared to AKI-D patients who did not recover, AKI-D patients who recovered were younger, more likely to be white, had higher baseline eGFR, and were less likely to have pre-existing heart failure and other CVD, hypertension, diabetes, or dyslipidemia (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of study cohort. Baseline was defined as pre-hospitalization for patients with dialysis-requiring acute kidney injury and at the time of dialysis initiation for patients without dialysis-requiring acute kidney injuryOverallESRD Not Due to AKI-DESRD Due to AKI-DRecovered AKI-DCharacteristic(*n* = 6984)(*n* = 3772)(*n* = 1865)(*n* = 1347)*P*-ValueAge, years, mean (SD)64.9 (14.0)64.8 (13.9)66.7 (13.5)62.9 (14.7)\< 0.001Female Gender, n (%)3007 (43.1)1663 (44.1)806 (43.2)538 (39.9)\< 0.05Self-reported Race, n (%) White/European2787 (39.9)1295 (34.3)763 (40.9)729 (54.1)\< 0.001 Black/African American1128 (16.2)638 (16.9)337 (18.1)153 (11.4) Asian/Pacific Islander1397 (20.0)911 (24.2)322 (17.3)164 (12.2) Other/Unknown1672 (23.9)928 (24.6)443 (23.8)301 (22.3)Hispanic ethnicity, n (%)1412 (20.2)821 (21.8)363 (19.5)228 (16.9)\< 0.001Smoking status, n (%)\< 0.001 Current Smoker529 (7.6)228 (6.0)149 (8.0)152 (11.3) Former smoker2926 (41.9)1580 (41.9)809 (43.4)537 (39.9) Nonsmoker3529 (50.5)1964 (52.1)907 (48.6)658 (48.8)Cardiovascular history, n (%) Acute myocardial infarction373 (5.3)184 (4.9)135 (7.2)54 (4.0)\< 0.001 Coronary artery bypass graft surgery111 (1.6)54 (1.4)36 (1.9)21 (1.6)0.37 Percutaneous coronary intervention261 (3.7)128 (3.4)89 (4.8)44 (3.3)\< 0.05 Heart failure2162 (31.0)1092 (29.0)757 (40.6)313 (23.2)\< 0.001 Ischemic stroke or TIA323 (4.6)189 (5.0)88 (4.7)46 (3.4)0.06 Peripheral artery disease369 (5.3)264 (7.0)76 (4.1)29 (2.2)\< 0.001 Mitral and/or aortic valvular disease721 (10.3)313 (8.3)247 (13.2)161 (12.0)\< 0.001 Atrial flutter or fibrillation943 (13.5)408 (10.8)326 (17.5)209 (15.5)\< 0.001 Venous thromboembolism128 (1.8)53 (1.4)37 (2.0)38 (2.8)\< 0.01Other medical history, n (%) Diabetes mellitus4494 (64.3)2544 (67.4)1284 (68.8)666 (49.4)\< 0.001 Hypertension6409 (91.8)3688 (97.8)1721 (92.3)1000 (74.2)\< 0.001 Dyslipidemia5872 (84.1)3376 (89.5)1566 (84.0)930 (69.0)\< 0.001Body mass index, kg/m^2^, mean (SD)30.4 (7.7)29.8 (7.2)30.8 (8.0)31.6 (8.5)\< 0.001Systolic blood pressure, mmHg, mean (SD)134.0 (21.5)135.8 (20.0)135.9 (24.1)126.0 (19.8)\< 0.001Baseline medication use, n (%) Angiotensin converting enzyme inhibitor1587 (22.7)684 (18.1)441 (23.6)462 (34.3)\< 0.001 Angiotensin II receptor blocker1110 (15.9)615 (16.3)290 (15.5)205 (15.2)0.58 Beta blocker4403 (63.0)2590 (68.7)1179 (63.2)634 (47.1)\< 0.001 Calcium channel blocker3959 (56.7)2574 (68.2)1007 (54.0)378 (28.1)\< 0.001 Diuretic4738 (67.8)2746 (72.8)1300 (69.7)692 (51.4)\< 0.001 Alpha blocker1919 (27.5)1202 (31.9)504 (27.0)213 (15.8)\< 0.001 Aldosterone receptor antagonist272 (3.9)68 (1.8)101 (5.4)103 (7.6)\< 0.001 Nitrates1142 (16.4)626 (16.6)396 (21.2)120 (8.9)\< 0.001 Vasodilators1976 (28.3)1248 (33.1)570 (30.6)158 (11.7)\< 0.001 Antiarrhythmic drug156 (2.2)55 (1.5)54 (2.9)47 (3.5)\< 0.001 Statin4561 (65.3)2647 (70.2)1202 (64.5)712 (52.9)\< 0.001 Other lipid-lowering agent513 (7.3)294 (7.8)119 (6.4)100 (7.4)0.16 Non-aspirin antiplatelet agent526 (7.5)284 (7.5)160 (8.6)82 (6.1)\< 0.05 Low molecular weight heparin94 (1.3)28 (0.7)29 (1.6)37 (2.7)\< 0.001 Non-steroidal anti-inflammatory drug238 (3.4)41 (1.1)71 (3.8)126 (9.4)\< 0.001 Diabetic therapy2820 (40.4)1588 (42.1)796 (42.7)436 (32.4)\< 0.001Baseline laboratory values CKD-EPI eGFR, mL/min/1.73 m^2^  Median (interquartile range)11.7 (8.4--20.0)9.8 (7.6--12.4)14.2 (9.5--24.1)51.4 (30.6--77.0)\< 0.001  Missing, n (%)392 (5.6)57 (1.5)130 (7.0)205 (15.2) Urine dipstick proteinuria\< 0.001  Negative/Trace700 (10.0)218 (5.8)189 (10.1)293 (21.8)  1+999 (14.3)515 (13.7)279 (15.0)205 (15.2)  ≥2+4246 (60.8)2889 (76.6)1109 (59.5)248 (18.4)  Unknown1039 (14.9)150 (4.0)288 (15.4)601 (44.6)

Outcomes between ESRD due to AKI-D vs. ESRD not due to AKI-D {#Sec11}
------------------------------------------------------------

In unadjusted analyses, patients with incident ESRD due to AKI-D had higher all-cause death rates than patients with incident ESRD who did not experience AKI-D (Table [2](#Tab2){ref-type="table"}). Patients with incident ESRD due to AKI-D also had significantly higher crude heart failure hospitalization and ACS rates but no significant differences in stroke/TIA.Table 2Crude rates of all-cause death and cardiovascular outcomes after dialysis initiation, stratified by end-stage renal disease (ESRD) and dialysis-requiring acute kidney injury (AKI-D) statusOutcomeRate per 100 person-years (95% Confidence Interval)P-valueAll-Cause Death ESRD due to AKI-D23.58 (18.06--30.78)Ref ESRD not due to AKI-D9.51 (8.50--10.65)\< 0.0001 Recovered AKI-D17.17 (12.78--23.05)0.0004Hearth Failure Hospitalization ESRD due to AKI-D8.17 (5.09--13.11)Ref ESRD not due to AKI-D3.00 (2.45--3.67)\< 0.0001 Recovered AKI-D7.68 (4.66--12.65)0.5858Acute Coronary Syndrome ESRD due to AKI-D5.14 (3.17--8.33)Ref ESRD not due to AKI-D3.45 (2.86--4.17)0.0081 Recovered AKI-D2.21 (1.18--4.15)0.0003Stroke or Transient Ischemic Attack ESRD due to AKI-D3.53 (2.02--6.18)Ref ESRD not due to AKI-D2.68 (2.16--3.32)0.1168 Recovered AKI-D1.19 (0.54--2.65)0.0005

In multivariable analyses, compared to patients with incident ESRD due to AKI-D, those with incident ESRD not due to AKI-D had a significantly lower adjusted rate of all-cause death (adjusted hazard ratio \[aHR\] 0.56, 95% CI 0.47--0.67) (Fig. [1](#Fig1){ref-type="fig"}). After adjustment for potential confounders, ESRD not due to AKI-D was also associated with a lower adjusted rate of heart failure hospitalization (aHR 0.45, 0.30--0.70) but not ACS or stroke/TIA (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Multivariable association of all-cause mortality and cardiovascular events after dialysis initiation among patients with incident end-stage renal disease (ESRD) due to dialysis-requiring acute kidney injury (AKI-D), patients with incident ESRD not due to AKI-D, and patients with AKI-D who recovered. Models are adjusted for the following baseline covariates: age, gender, race, Hispanic ethnicity, smoking status, acute myocardial infarction, heart failure, ischemic stroke or transient ischemic attack, peripheral artery disease, mitral and/or aortic valvular disease, atrial flutter or fibrillation, venous thromboembolism, other thromboembolic events, coronary artery bypass surgery, percutaneous coronary intervention, diabetes mellitus, hypertension, dyslipidemia, hyperthyroidism, hypothyroidism, cirrhosis, chronic lung disease, diagnosed dementia, diagnosed depression, hospitalized bleed, body mass index, systolic blood pressure, eGFR, dipstick proteinuria, hemoglobin level, HDL cholesterol level, LDL cholesterol level, and pre-admission receipt of the following medications: ACE inhibitor, angiotensin II receptor blocker, antiarrhythmic drug, beta blocker, calcium channel blocker, diuretic, alpha blocker, any anti-hypertensive agent, aldosterone receptor antagonist, nitrates, vasodilators, statin, other lipid-lowering agent, non-aspirin antiplatelet agent, low molecular weight heparin, non-steroidal anti-inflammatory drug, and diabetic therapy

In sensitivity analyses excluding AKI-D patients with pre-existing eGFR ≤24 ml/min/1.73 m^2^, we obtained similar crude and adjusted results for death (aHR 0.43, 0.28--0.67) and heart failure hospitalization (aHR 0.61, 0.27--1.37).

Outcomes between recovery vs. non-recovery from AKI-D {#Sec12}
-----------------------------------------------------

Patients who recovered from AKI-D had lower crude rates of all-cause death, ACS, and stroke/TIA compared to those who did not recover (Table [2](#Tab2){ref-type="table"}). In multivariable analyses, recovery from AKI-D was independently associated with lower mortality (aHR 0.70, 0.55--0.88) compared with non-recovery (Fig. [1](#Fig1){ref-type="fig"}). However, there were no significant adjusted differences in rates of heart failure, ACS, or stroke/TIA (Fig. [1](#Fig1){ref-type="fig"}). We obtained similar crude and adjusted results in our sensitivity analyses (aHR for death 0.59, 0.44--0.80).

Discussion {#Sec13}
==========

Healthy People 2020 includes as key objectives to reduce all-cause and CVD-related mortality in ESRD patients \[[@CR34]\]. While the U.S. Renal Data System tracks long-term mortality in ESRD patients, ascertainment of both early death and CVD events, as well as understanding potentially modifiable risk factors, has been much more challenging. Our study based within a large, community-based population helps to fill this important knowledge gap.

Our study has several key findings. First, a large fraction (one third) of incident ESRD patients in our cohort developed ESRD via AKI-D. Because we censored patients who died within 90 days of RRT initiation, one caveat is that the numbers of incident ESRD patients in both the AKI-D and non-AKI-D groups were reduced. It can also be clinically challenging to determine whether patients with chronic kidney disease who initiate dialysis during a hospitalization do so because of progression of underlying disease versus superimposed acute injury. However, prior single-center and VA data have reported similar proportions of incident ESRD patients initiating dialysis in the hospital \[[@CR35]--[@CR37]\]. Therefore, our finding that patients with incident ESRD due to AKI-D have significantly higher adjusted all-cause death rates compared to incident ESRD patients without AKI-D indicates that the large number of patients who reach ESRD via AKI-D may explain, in part, the high early mortality rate in the overall ESRD population.

Second, we found that patients with incident ESRD due to AKI-D have higher rates of heart failure hospitalization after RRT initiation than ESRD patients without AKI-D. These findings extend prior observations that patients with abrupt decline in renal function before ESRD have higher rates of heart failure events in the three months before dialysis initiation compared to those who did not experience an abrupt decline \[[@CR20]\], and patients who initiate dialysis due to volume overload have higher mortality rates \[[@CR38]\]. In our cohort, patients with ESRD due to AKI-D were more likely to have pre-existing heart failure compared to patients with ESRD not due to AKI-D. Taken together, these data suggest that the higher mortality rates among those who experienced AKI-D leading to ESRD may be driven, in part, by a greater burden of heart failure. This finding suggests that better fluid management and more systematic use of evidence-based therapies for heart failure may potentially improve outcomes in this vulnerable population.

Third, our finding that AKI-D patients who recovered had lower adjusted mortality compared to those who did not recover highlights yet another reason we urgently need to devise treatment strategies to enhance or hasten recovery from AKI-D. Most prior studies evaluating long-term sequelae after recovery from AKI-D compared AKI-D patients to matched controls without AKI-D \[[@CR13], [@CR14]\], while we were able to distinguish outcome differences between those who did and did not recover. Although one small study reported that patients who recovered after AKI-D had lower 2-year mortality compared to patients who did not recover after AKI-D, our cohort was substantially larger and able to account for a larger set of potential confounders \[[@CR39]\].

Finally, although we hypothesized that patients who recovered after AKI-D would have better outcomes, we found that even those who are able to discontinue dialysis remain at high risk for cardiovascular events, particularly hospitalizations for heart failure. We examined early outcomes after RRT initiation because mortality is particularly high during this time \[[@CR8]\] and because AKI-D may be linked to elevated short-term CVD risk \[[@CR16]\]. Several studies in the general population have suggested a transient increase in risk of stroke or myocardial infarction after an episode of infection or systemic inflammation \[[@CR40], [@CR41]\], and another study found that septicemia is a CVD risk factor in ESRD patients \[[@CR42]\]. However, we did not find significant differences in outcomes that may be related to arterial plaque rupture or occlusion (e.g., ACS, stroke/TIA). Instead, AKI-D leading to ESRD was most strongly associated with all-cause death and excess heart failure events, which is also linked to aberrations in multiple signaling pathways related to inflammation, fluid overload, myocardial injury, and ventricular stress \[[@CR43], [@CR44]\].

Strengths of our study included the large number of AKI-D cases, which allowed us to examine the impact of renal recovery on clinical outcomes. In contrast to the majority of studies examining highly selected populations (e.g., post-operative acute kidney injury, contrast-induced nephropathy) \[[@CR9]\], our study included a broad mix of AKI-D etiologies, which increases generalizability. We were also able to examine the pre-ESRD disease course (prior medication use, medical history, and other clinical features) to characterize incident ESRD subgroups and add important new insights on the transition to ESRD via AKI-D as well as the impact of recovery from AKI-D on CVD outcomes \[[@CR8], [@CR37], [@CR39], [@CR45], [@CR46]\]. Furthermore, our data were much more rigorous than data collected via the Medical Evidence Report that is used for registration into the national U.S. Renal Data System \[[@CR47]--[@CR50]\].

Limitations include that some patients classified in our study as having AKI-D may have initiated dialysis as inpatients because of progression of advanced chronic kidney disease rather than true AKI-D. However, for the comparison of patients with ESRD due to vs. not due to AKI-D, this type of misclassification would bias results toward the null, which bolsters our confidence in the differences we detected. We did not have details on inpatient dialysis prescriptions (e.g., modality, dose, or anticoagulation use), or etiology of AKI-D, including underlying cardiorenal physiology. Only insured patients from Northern California enrolled in an integrated health care delivery system were included, but the KPNC membership is highly representative of the local surrounding and statewide population, which argues for greater generalizability \[[@CR23]\]. While we relied on electronic medical records for key data elements, our data sources are much more comprehensive than administrative databases and include clinical data elements (instead of primarily relying on diagnostic or procedural codes) \[[@CR21], [@CR28], [@CR30]--[@CR32]\]. Because we wanted to explore how recovery from AKI-D influences outcomes, we were only able to compare outcomes that occurred between 90 days after RRT initiation and up to 1 year thereafter. Conditioning on survival to 90 days (in all three subgroups examined) may introduce immortal time bias, but this potential bias would likely decrease the observed effect size because the sickest AKI-D patients in the non-recovery group who died early would be excluded. We also had to exclude a small number (*n* = 182) of patients who were hospitalized for ≥ 90 days during their AKI-D hospitalization, but again these patients were likely the sickest AKI-D patients who would have been at highest risk for early death and CVD events. However, our design did preclude addressing potential differences in death and CVD event rates during the first 90 days, which may be higher as compared to the subsequent 1-year follow-up period.

Conclusions {#Sec14}
===========

In conclusion, we found that patients who transition to ESRD via AKI-D are at higher risk for short-term death and heart failure hospitalization compared to those who start chronic dialysis without experiencing AKI-D. Our findings indicate that the high short-term mortality in incident ESRD patients may be explained, at least in part, by the subset of patients who developed ESRD via AKI-D. Furthermore, our findings suggest that this subset of incident ESRD patients may have worse outcomes because of pre-existing heart failure. Recovery from AKI-D was also independently associated with lower short-term mortality. Collectively, these findings suggest that aggressive surveillance for and medical management of heart failure in ESRD patients may be a potential strategy for reducing early mortality after AKI-D. Further studies are warranted to evaluate whether promotion of renal recovery from AKI-D and systematic surveillance and intervention for heart failure can improve outcomes in this vulnerable patient population.
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